Sign Up For Free » Here's a closer look at three discounted S&P 500 dividend stocks you can feel good about buying and ...

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Revenues rose 7% year over year (9% excluding Fx) to $15.62 billion driven by Keytruda, new products like Winrevair and strong performance of the Animal Health segment, partially offset by lower ...

Wall Street is generally afraid of uncertainty, but with adversity also comes opportunity. Find out my 2 picks that have well ...

MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo ...

Other contributing factors included the successful launch of WINREVAIR and the robust performance of its Animal Health division. For 2025, the company expects sales between $64.1 billion and $65.6 ...

the successful roll-out of WINREVAIR and healthy performance of its Animal Health business. Merck & Co., Inc. (NYSE:MRK) continues to progress its pipeline, advance key clinical programs and ...

The first-in-class activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, given the trade name Winrevair, has been cleared to improve exercise capacity, improve lung function, and reduce the ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...